CDD-1845

• Description:

  CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants[1].

• UNSPSC:

  12352005

• Target:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/cdd-1845.html

• Purity:

  99.60

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(NC)CCCN1C(C2=C(C=CC=C3)C3=CN=C2)=NC4=C1C(C(N[C@@H](C)C5=CC=C(C=CC=C6)C6=C5)=O)=CC=C4

• Molecular Formula:

  C34H31N5O2

• Molecular Weight:

  541.64

• References & Citations:

  [1]Ravikumar Jimmidi, et al. DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors. Commun Chem. 2023 Aug 4;6 (1) :164.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2894104-50-6]